All News

The expert oncologist spoke about the conclusions drawn from the COVID-19 and Cancer Consortium, as well as the importance of prognostic biomarkers.

This study demonstrated a possible advantage in overall survival for patients taking NSAIDs during chemoradiation for head and neck squamous cell carcinoma.

The tool was shown to be a reliable and accurate tool for measuring patient-reported financial toxicity in patients with head and neck cancer.

A study published in Cancer found that potentially avoidable hospitalizations for veterans with cancer who received chemotherapy through Medicare were more likely compared to those who received chemotherapy through the Veterans Health Administration.

The expert from the CUNY School of Medicine spoke about a recent study which indicated that Hispanic adults trust a wide variety of health information sources, suggesting the need for targeted information.

The dose escalation and expansion study is evaluating the safety and tolerability of ONCR-177 in patients with cancer and determining the recommended phase 2 dose.

Researchers were able to establish possible mechanisms that may contribute to racial differences in incidence, patterns of presentation, and survival in patients with DLBCL with African ancestry.

The MD Anderson Cancer Center expert spoke about the key takeaways from a trial designed to test whether pre and/or post-test genetic counseling is needed to optimally deliver online accessible genetic testing.

Researchers in Canada launched a phase 3 trial of IMM-101, titled CCTG IC.8, with the hope of strengthening the immune system of patients with cancer.

Data from an abstract presented at the 2020 ASCO Virtual Scientific Program found that in-person visits at the University of Washington Urology Clinic were more time consuming and expensive for out-of-state patients and patients living in rural areas than telemedicine visits.

The committee voted 12-0 in favor of the demonstrated benefit of belantamab mafodotin as monotherapy outweighing the risks for patients with relapsed or refractory multiple myeloma who have received at least 4 prior therapies.

FACT-Leu was found to be a suitable outcome measure for patients not eligible for intensive therapy in acute myeloid leukemia clinical trials.

A study of patients with cancer suspected of having COVID-19 indicated that the death rate at 30 days after diagnosis is high, both in patients with and without documented SARS-CoV-2 infection on RT-PCR.

The co-leader of the NCI Center for Cancer Research Liver Cancer Program discussed the clinical utility of the blood test and how it could potentially change liver cancer diagnoses moving forward.

Researchers examined the effectiveness of telehealth in addressing rural-urban disparities in cancer care by establishing and analyzing synaptic knowledge networks presented at the 2020 ASCO Virtual Scientific Program.

The study showed that the addition of atezolizumab to bevacizumab, paclitaxel, and carboplatin as a front-line treatment in women with newly diagnosed advanced stage ovarian cancer did not meet its primary endpoint of progression-free survival.

The Seattle Cancer Care Alliance Expert offered background on cohort A of the KEYNOTE-427 trial.

The study results confirmed that the triple-negative breast cancers emergence among young compared with elderly patients can be completely different entities.

Researchers suggested that the use of the oral agent over a prolonged period of time should now be considered part of the overall treatment plan in acute promyelocytic leukemia.

The chronic lymphocytic leukemia expert spoke about the possible use of venetoclax plus dose-adjusted R-EPOCH in various hematologic patient populations.

The expert discussed study methods from the NRG Oncology/Gynecologic Oncology Group (GOG) study presented at the 2020 ASCO Virtual Program.

Findings suggested that conventional mammography screening performance metrics underestimate the interval cancer rate of a mammography screening episode.

At the 2020 ASCO Virtual Program, Jun J. Mao, MD, MSCE, presented a study designed to evaluate the comparative effectiveness of electro-acupuncture and auricular acupuncture versus usual care in managing pain in cancer survivors.

Data from the registry suggested that in patients with cancer and COVID-19, cancer that is progressing was independently associated with an increased risk of death.

Researchers found that dense allele-specific DNA methylation (ASM) mapping in normal samples plus cancer samples reveals possible candidate regulatory sequence polymorphisms (rSNPS) that are difficult to find by other approaches.

The FDA accepted and granted priority review to a supplemental biologics license application for pembrolizumab as monotherapy for the treatment of adult patients with relapsed or refractory classical Hodgkin lymphoma.

The president and CEO of Cancer Treatment Centers of America highlighted the importance in caring for patients with cancer even in the midst of the coronavirus disease 2019 (COVID-19) pandemic.

The expert explained how states that expanded Medicaid coverage saw a steeper decline in cancer mortality rates, and next steps for further evaluation.

Merck and Eisai announced that the FDA issued a complete response letter to its accelerated approval applications for the combination use of pembrolizumab plus lenvatinib to treat patients with unresectable hepatocellular carcinoma.

At the 2020 ASCO Virtual Program, Courtney DiNardo, MD, presented on a study of the combination therapy consisting of ivosenidib plus venetoclax with or without azacytidine patients with IDH1-mutated acute myeloid leukemia.